Skip to content

Clinical trials

Latent Tuberculosis trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Latent Tuberculosis Phase: Not applicable Clear all

52 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20071
20081
20093
20144
20151
20164
20172
20182
20194
20205
20212
20224
20233
20241
20254
202610

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed28
Not yet recruiting8
Recruiting5
Unknown status5
Active, not recruiting2
Terminated2
Enrolling by invitation1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Johns Hopkins University4
Liverpool School of Tropical Medicine3
Queen Mary University of London2
Seoul National University Hospital2
University of California, San Francisco2
Aarhus University Hospital1
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.1
Ankara City Hospital Bilkent1
Assistance Publique - Hôpitaux de Paris1
Bahir Dar University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Latent Tuberculosis52
Tuberculosis26
Acquired Immunodeficiency Syndrome6
Tuberculosis, Pulmonary4
HIV Infections3
Asthma1
Diabetes Mellitus1
Disease1
Hypersensitivity1
Inflammation1

Trials

Showing 76 to 52 of 52. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.